Key Points
- Jeffrey Zerillo sold 1,207 PBH shares on May 5 at an average price of $54.99 for $66,372.93, leaving him with 42,820 shares (a 2.74% decline in his ownership).
- He also sold 346 shares on May 5 at $55.32 and 1,000 shares on Feb 11 at $65.93, showing multiple recent insider dispositions.
- Prestige trades around $54.49 with a 52‑week range of $51.24–$89.37; the company recently missed quarterly EPS and revenue estimates, while analysts maintain a consensus Moderate Buy with an average target of $74.75.
Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 1,207 shares of the business's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Jeffrey Zerillo also recently made the following trade(s):
- On Tuesday, May 5th, Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $55.32, for a total transaction of $19,140.72.
- On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00.
Prestige Consumer Healthcare Price Performance
Shares of PBH opened at $54.49 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The firm's 50 day moving average price is $60.23 and its 200 day moving average price is $61.92. The company has a market cap of $2.58 billion, a P/E ratio of 14.42, a PEG ratio of 1.62 and a beta of 0.40. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million during the quarter, compared to analysts' expectations of $286.93 million. During the same quarter in the previous year, the business posted $1.22 EPS. The business's quarterly revenue was down 2.4% compared to the same quarter last year. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on PBH shares. Oppenheimer reduced their price objective on shares of Prestige Consumer Healthcare from $77.00 to $65.00 and set an "outperform" rating for the company in a research report on Thursday. Jefferies Financial Group reduced their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $74.75.
Check Out Our Latest Stock Report on PBH
Institutional Trading of Prestige Consumer Healthcare
Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its holdings in shares of Prestige Consumer Healthcare by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company's stock worth $158,414,000 after buying an additional 91,710 shares during the last quarter. State Street Corp lifted its position in Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company's stock worth $122,917,000 after acquiring an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 1.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company's stock worth $98,776,000 after acquiring an additional 21,085 shares during the period. Morgan Stanley grew its stake in shares of Prestige Consumer Healthcare by 6.3% in the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company's stock valued at $74,209,000 after purchasing an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 5.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company's stock valued at $45,568,000 after purchasing an additional 35,126 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.
About Prestige Consumer Healthcare
(
Get Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
